Everolimus improves progression-free survival for patients with advanced, nonfuctional neuroendocrine tumors
Sunday, September 27, 2015 - 20:30
in Health & Medicine
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors of the lung and gastrointestinal tract.